PD-1+ Treg cells: a foe in cancer immunotherapy?

Halil-Ibrahim Aksoylar; Vassiliki A Boussiotis

doi:10.1038/s41590-020-0801-7

PD-1⁺ T_reg cells: a foe in cancer immunotherapy?

Nat Immunol. 2020 Nov;21(11):1311-1312. doi: 10.1038/s41590-020-0801-7.

Authors

Halil-Ibrahim Aksoylar^{1

2}, Vassiliki A Boussiotis^{3

4}

Affiliations

¹ Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
² Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
³ Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. vboussio@bidmc.harvard.edu.
⁴ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. vboussio@bidmc.harvard.edu.

Abstract

The mechanisms that drive responses to PD-1-blocking immunotherapy in some but not all patients have been puzzling. A new study suggests that the balance of PD-1 expression levels between CD8⁺ T cells and T_reg cells might provide an answer.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Humans
Immunotherapy
Neoplasms* / therapy
Programmed Cell Death 1 Receptor
T-Lymphocytes, Regulatory*
Treatment Outcome

Substances

Programmed Cell Death 1 Receptor

Abstract

Publication types

MeSH terms

Substances

Grants and funding